Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial.

Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial.
复制标题

DOI:
10.1186/s13063-021-05123-w
复制
发表时间:
2021-02-23
期刊:
影响因子:
2.5
通讯作者:
Wu R
Wu R
中科院分区:
医学4区
文献类型:
--
作者:
Liu C;Kang D;Xiao J;Huang Y;Peng X;Wang W;Xie P;Yang Y;Zhao J;Wu R

文献摘要

参考文献

被引文献

相似文献

Atypical antipsychotic medications, which are effective for the treatment of schizophrenia and bipolar disorder, are associated with features of metabolic syndrome, such as weight gain, hyperglycemia, dyslipidemia, and insulin resistance. Although there are a few studies on the effects of dietary fiber or probiotics on weight loss in obese people, no published trials have reported the efficacy of dietary fiber and probiotics on reducing atypical antipsychotic-induced weight gain. For this 12-week randomized, double-blind, placebo-controlled study, 100 patients with a weight gain of more than 10% after taking atypical antipsychotic medications were recruited. Participants were randomized to four groups as follows: probiotics (840 mg twice daily (bid)) plus dietary fiber (30 g bid), probiotics (840 mg bid) plus placebo, placebo plus dietary fiber (30 g bid), or placebo group. The primary outcome was the change in body weight. Secondary outcomes included changes in metabolic syndrome parameters, appetite score, biomarkers associated with a change in weight, and gut microbiota composition and function. To date, this is the first randomized, placebo-controlled, double-blinded trial investigating the efficacy of dietary fiber and probiotics alone and in combination to reduce metabolic side effects induced by atypical antipsychotic medications. If effective, it is possible to conclude that dietary fiber and probiotics can reduce atypical antipsychotic-induced metabolic side effects. ClinicalTrials.gov NCT03379597. Registered on 19 November 2017. The online version contains supplementary material available at 10.1186/s13063-021-05123-w.
DOI: 10.2337/db06-1491
发表时间: 2007-07-01
期刊: DIABETES
影响因子: 7.7
作者:
Cani, Patrice D.;Amar, Jacques;Burcelin, Remy
通讯作者: Burcelin, Remy
DOI: 10.4088/jcp.v67n0812
发表时间: 2006-08-01
影响因子: 5.3
作者:
Alvarez-Jimenez, Mario;Gonzalez-Blanch, Cesar;Crespo-Facorro, Benedicto
通讯作者: Crespo-Facorro, Benedicto
DOI: 10.3389/fmicb.2017.00563
发表时间: 2017
影响因子: 5.2
作者:
Dahiya DK;Renuka;Puniya M;Shandilya UK;Dhewa T;Kumar N;Kumar S;Puniya AK;Shukla P
通讯作者: Shukla P
DOI: 10.1186/1476-511x-10-116
发表时间: 2011-07-12
影响因子: 4.5
作者:
An HM;Park SY;Lee DK;Kim JR;Cha MK;Lee SW;Lim HT;Kim KJ;Ha NJ
通讯作者: Ha NJ
DOI: 10.1136/gutjnl-2016-313271
发表时间: 2017-11
期刊: Gut
影响因子: 24.5
作者:
Vandeputte D;Falony G;Vieira-Silva S;Wang J;Sailer M;Theis S;Verbeke K;Raes J
通讯作者: Raes J